MAR 1 7 2004 SE AI

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Ceriani, R. L. et al.

: Art Unit: 1642

Serial. No:

To be Assigned

: Examiner: Dr M.T.Davis

Filing Date:

January 2, 2002

For: FU

FUSION PROTEIN WITH 46 KDALTON HMFG DIFFERENTIATION ANTIGEN

BINDING SPECIFICITY, COMPOSITION, KIT & METHODS

DECLARATION

Honorable Commissioner for Patents Washington, D.C. 20231

Sir/Madam:

I, Viviana Amzel, hereby state that the paper copy of the sequence listing submitted herewith in accordance with 37 CFR 1.825(a) and (b), is to the best of my knowledge the same as the computer copy of the Sequence Listing section filed in the parent application, and that the sequences correspond to the sequences in the original application.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted.

CANCER RESEARCH INSTITUTE

11/3/03

Viviana Amzel, Ph.D. Reg. No. 30,930

Attorney for the Applicant

P.O.Box 159 Gladwyne, PA 19035 610-649-0609 Ph. 240-359-0299 Fax

I hereby certify that this paper and fee is being deposited with the United States Postal Service "First Class Mail" service under 37 CFR 1.8 on November 3, 2003, and is addressed to the Assistant Commissioner for Patents, Washington, D.C., 20231, by Viviana Amzel.

SIGNATURE